“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome

€3.03

SKU: product-article-15337 Category: General

Description
Reviews (0)

Description

PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome

Reviews

There are no reviews yet.

Be the first to review “Article: PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome”

You must be logged in to post a review.

Top

Article: PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome

Description

Reviews

Related products

Article: Highlights in breast cancer

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

Article: Highlights in breast cancer

Article: Calendar of events